742 products have been evaluated, 278 countries have been collected, and 757 products have been approved without reference

Consistency evaluation Since 2016, 289 as the vanguard of the start-up to the current number of products that have been passed (according to the merger of generic dosage forms - based on the collection and collection rules) is 742, 1--7 batches of national chemical drugs are 278, 57 batches of reference preparations are published (officially announced), 58--61 batches have been solicited

Comparison of applications for conformity evaluation with approvals

The over-evaluation mentioned in this article includes (original research, reference, over-evaluation, and deemed over-evaluation).

Table 1: Applications and approvals from 2017 to August 2022

(Data source: NMPA CDE Medicine Rongyun, etc.

Table 2: As of August 30, 2022, drug evaluation, collection, reference, etc

(Data source: NMPA CDE Medicine Rongyun, etc.

The national procurement that makes pharmaceutical companies and pharmaceutical people feel the "cold" and the corresponding consistency evaluation are mainly concentrated in 278 + 83 + 64 = 425 products, and 317 products are currently only two evaluated

Among the 742 products that have been evaluated, there are nearly 140 or so products that are not in the medical insurance directory, that is to say, the 1486 Western medicines in the medical insurance directory (2021 version) have 1486-742 (evaluated) + 140 (non-medical insurance products have been evaluated) - 16 (national 6 insulin) = 868 products

Well, the opportunities in the theory are in these numbers

(Data source: NMPA CDE Medicine Rongyun, etc.

Table 4: As of August 30, 2022, the three companies have been rated

(Data source: NMPA CDE Medicine Rongyun, etc.

When this wave of "gathering" that lasts for a decade or more comes to an end, this opportunity may also disappear, at least for now